Payment overview · 2025
General Payments
$687.90
34 reported records · 13 companies
Healthcare provider profile · identity verified
Whitney Reed, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · JACKSONVILLE, AR · NPI 1184091415
Verified facts
What the public records show
CMS Open Payments records show Whitney Reed, APRN received $687.90 in general payments during 2025 across 34 reported records.
ABBVIE INC. accounted for 54.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $377.01 | 54.8% | 17 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $61.15 | 8.9% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.21 | 4.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.88 | 4.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.46 | 4.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.81 | 4.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.29 | 3.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.74 | 3.5% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.80 | 2.9% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $15.93 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.54 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.54 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.54 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $687.90 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $197.74 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $179.27 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $174.08 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $61.15 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $53.75 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $32.21 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 94 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
94 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 338 | 70 |
| Omeprazole | Omeprazole | 279 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 278 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 78 |
| Gabapentin | Gabapentin | 268 | 69 |
| Lisinopril | Lisinopril | 241 | 58 |
| Losartan Potassium | Losartan Potassium | 204 | 52 |
| Clonazepam | Clonazepam | 199 | 41 |
| Meloxicam | Meloxicam | 185 | 49 |
| Potassium Chloride | Potassium Chloride | 161 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 42 |
| Metformin Hcl | Metformin Hcl | 140 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 132 | 33 |
| Jardiance | Empagliflozin | 131 | 29 |
| Tramadol Hcl | Tramadol Hcl | 128 | 33 |
| Trazodone Hcl | Trazodone Hcl | 122 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 44 |
| Ozempic | Semaglutide | 115 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 31 |
| Furosemide | Furosemide | 110 | 34 |
| Montelukast Sodium | Montelukast Sodium | 110 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 21 |
| Sertraline Hcl | Sertraline Hcl | 97 | 23 |
| Mounjaro | Tirzepatide | 94 | 15 |
| Alprazolam | Alprazolam | 91 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 89 | 22 |
| Azithromycin | Azithromycin | 88 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 27 |
| Methocarbamol | Methocarbamol | 87 | 25 |
| Eliquis | Apixaban | 85 | 16 |
| Simvastatin | Simvastatin | 85 | 24 |
| Glipizide | Glipizide | 82 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 81 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 38 |
| Allopurinol | Allopurinol | 77 | 17 |
| Buspirone Hcl | Buspirone Hcl | 75 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 59 | 19 |
| Fluconazole | Fluconazole | 59 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Topiramate | Topiramate | 52 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 18 |
| Lorazepam | Lorazepam | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Glipizide Er | Glipizide | 44 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 12 |
| Atenolol | Atenolol | 43 | suppressed |
| Estradiol | Estradiol | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 14 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Prednisone | Prednisone | 35 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 30 |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 14 |
| Promethazine Hcl | Promethazine Hcl | 32 | 14 |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 11 |
| Baclofen | Baclofen | 27 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 19 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Wegovy | Semaglutide | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Nystatin | Nystatin | 22 | 15 |
| Vilazodone Hcl | Vilazodone Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 12 |
| Quviviq | Daridorexant Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Olanzapine | Olanzapine | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Belsomra | Suvorexant | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $687.90 · 34 records | ABBVIE INC. | CAPLYTA, CARDIOMEMS, GRAFIX PL, JARDIANCE, JOURNAVX, MOUNJARO, NUZYRA, Ozempic, QULIPTA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error